journal article·2024-04Open access

Nanoparticle Targeting in Chemo‐Resistant Ovarian Cancer Reveals Dual Axis of Therapeutic Vulnerability Involving Cholesterol Uptake and Cell Redox Balance

Yinu Wang, Andrea E. Calvert, Horacio Cardenas, Jonathon S. Rink, Dominik Nahotko, Wenan Qiang, C. Estelle Ndukwe, Fukai Chen, Russell Keathley, Yaqi Zhang, Ji‐Xin Cheng, C. Shad Thaxton, Daniela Matei

Advanced Science· Volume 11· Issue 13

Abstract

Abstract Platinum (Pt)‐based chemotherapy is the main treatment for ovarian cancer (OC); however, most patients develop Pt resistance (Pt‐R). This work shows that Pt‐R OC cells increase intracellular cholesterol through uptake via the HDL receptor, scavenger receptor type B‐1 (SR‐B1). SR‐B1 blockade using synthetic cholesterol‐poor HDL‐like nanoparticles (HDL NPs) diminished cholesterol uptake leading to cell death and inhibition of tumor growth. Reduced cholesterol accumulation in cancer cells induces lipid oxidative stress through the reduction of glutathione peroxidase 4 (GPx4) leading to ferroptosis. In turn, GPx4 depletion induces decreased cholesterol uptake through SR‐B1 and re‐sensitizes OC cells to Pt. Mechanistically, GPx4 knockdown causes lower expression of the histone acetyltransferase EP300, leading to reduced deposition of histone H3 lysine 27 acetylation (H3K27Ac) on the sterol regulatory element binding transcription factor 2 (SREBF2) promoter and suppressing expression of this key transcription factor involved in the regulation of cholesterol metabolism. SREBF2 downregulation leads to decreased SR‐B1 expression and diminished cholesterol uptake. Thus, chemoresistance and cancer cell survival under high ROS burden obligates high GPx4 and SR‐B1 expression through SREBF2. Targeting SR‐B1 to modulate cholesterol uptake inhibits this axis and causes ferroptosis in vitro and in vivo in Pt‐R OC.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Cancer, Lipids, and Metabolism · Ferroptosis and cancer prognosis · Cholesterol and Lipid Metabolism

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Obstetrics and Gynecology Feinberg School of Medicine Northwestern University Chicago IL 60611 USA

Simpson Querrey Institute for BioNanotechnology Feinberg School of Medicine Northwestern University Chicago IL 60611 USA

Division of Hematology/ Oncology Department of Medicine Feinberg School of Medicine Northwestern University Chicago IL 60611 USA

Center for Developmental Therapeutics,Feinberg School of Medicine Northwestern University Evanston IL 60208 USA

Robert H. Lurie Comprehensive Cancer Center Northwestern University Chicago IL 60611 USA

Department of Physics Boston University Boston MA 02215 USA

Department of Urology Feinberg School of Medicine Northwestern University Chicago IL 60611 USA

Jesse Brown Veteran Affairs Medical Center Chicago IL 60612 USA

References (70)

Show source-provided references
1. 10.1200/JCO.2013.51.448910.1200/JCO.2013.51.4489 ↗
2. 10.1200/JCO.2001.19.14.331210.1200/JCO.2001.19.14.3312 ↗
3. 10.1001/jamaoncol.2018.625810.1001/jamaoncol.2018.6258 ↗
4. 10.1093/annonc/mdr53110.1093/annonc/mdr531 ↗
5. 10.1200/JCO.2005.16.00610.1200/JCO.2005.16.006 ↗
6. 10.1016/S1470-2045(19)30029-410.1016/S1470-2045(19)30029-4 ↗
7. 10.1038/s41598-018-22640-y10.1038/s41598-018-22640-y ↗
8. 10.1158/0008-5472.CAN-20-148810.1158/0008-5472.CAN-20-1488 ↗
9. 10.1038/s41467-022-32101-w10.1038/s41467-022-32101-w ↗
10. 10.1186/s12967-015-0511-310.1186/s12967-015-0511-3 ↗
11. 10.3389/fcell.2021.62290810.3389/fcell.2021.622908 ↗
12. 10.3389/fcell.2022.81928110.3389/fcell.2022.819281 ↗
13. 10.1016/j.cmet.2014.01.01910.1016/j.cmet.2014.01.019 ↗
14. 10.3390/cells904082810.3390/cells9040828 ↗
15. 10.1002/ijc.3175810.1002/ijc.31758 ↗
16. 10.1038/s41416-021-01460-410.1038/s41416-021-01460-4 ↗
17. 10.1155/2016/912523810.1155/2016/9125238 ↗
18. 10.1111/febs.1501810.1111/febs.15018 ↗
19. 10.1016/j.molcel.2019.09.00810.1016/j.molcel.2019.09.008 ↗
20. 10.3390/cells805038910.3390/cells8050389 ↗
21. 10.1016/j.atherosclerosis.2018.08.03210.1016/j.atherosclerosis.2018.08.032 ↗
22. 10.1194/jlr.R08312110.1194/jlr.R083121 ↗
23. 10.3109/1061186090315641910.3109/10611860903156419 ↗
24. 10.3389/fphar.2016.0046610.3389/fphar.2016.00466 ↗
25. 10.1158/1535-7163.MCT-17-098110.1158/1535-7163.MCT-17-0981 ↗
26. 10.1038/srep1572410.1038/srep15724 ↗
27. 10.1194/jlr.M05463510.1194/jlr.M054635 ↗
28. 10.1073/pnas.121365711010.1073/pnas.1213657110 ↗
29. 10.18632/oncotarget.1449410.18632/oncotarget.14494 ↗
30. 10.1074/jbc.RA120.01488810.1074/jbc.RA120.014888 ↗
31. 10.1021/nn203545710.1021/nn2035457 ↗
32. 10.1021/ja808856z10.1021/ja808856z ↗
33. 10.1021/cr03069810.1021/cr030698 ↗
34. 10.1158/0008-5472.CAN-19-021510.1158/0008-5472.CAN-19-0215 ↗
35. 10.1158/2159-8290.CD-21-021110.1158/2159-8290.CD-21-0211 ↗
36. 10.1016/j.redox.2023.10267810.1016/j.redox.2023.102678 ↗
37. 10.1038/srep1572410.1038/srep15724 ↗
38. 10.1016/j.fertnstert.2016.01.01210.1016/j.fertnstert.2016.01.012 ↗
39. 10.1021/acs.molpharmaceut.7b0071010.1021/acs.molpharmaceut.7b00710 ↗
40. 10.1038/s41586-019-0945-510.1038/s41586-019-0945-5 ↗
41. 10.1038/nature2429710.1038/nature24297 ↗
42. 10.1210/endo.140.12.722010.1210/endo.140.12.7220 ↗
43. 10.1161/01.ATV.0000147896.69299.8510.1161/01.ATV.0000147896.69299.85 ↗
44. 10.1172/JCI021559310.1172/JCI0215593 ↗
45. 10.1038/s41467-021-21707-110.1038/s41467-021-21707-1 ↗
46. 10.1038/nature1124710.1038/nature11247 ↗
47. 10.1093/nar/gkx108110.1093/nar/gkx1081 ↗
48. 10.1593/neo.10137210.1593/neo.101372 ↗
49. 10.1016/j.bbalip.2019.15852510.1016/j.bbalip.2019.158525 ↗
50. 10.1038/s41586-019-0945-510.1038/s41586-019-0945-5 ↗
51. 10.1158/2159-8290.CD-21-021110.1158/2159-8290.CD-21-0211 ↗
52. 10.1038/s41467-021-25354-410.1038/s41467-021-25354-4 ↗
53. 10.1038/nature2429710.1038/nature24297 ↗
54. 10.1038/nature2300710.1038/nature23007 ↗
55. 10.1073/pnas.121365711010.1073/pnas.1213657110 ↗
56. 10.1182/bloodadvances.202000310010.1182/bloodadvances.2020003100 ↗
57. 10.1073/pnas.211034811910.1073/pnas.2110348119 ↗
58. 10.1016/j.redox.2018.09.01310.1016/j.redox.2018.09.013 ↗
59. 10.1371/journal.pone.008907010.1371/journal.pone.0089070 ↗
60. 10.1172/JCI15159110.1172/JCI151591 ↗
61. 10.1016/j.ccr.2013.10.01310.1016/j.ccr.2013.10.013 ↗
62. Auersperg N. · Lab Invest. · 1994 · 71 · 510
63. 10.1074/jbc.RA120.01488810.1074/jbc.RA120.014888 ↗
64. 10.1158/0008-5472.CAN-09-194710.1158/0008-5472.CAN-09-1947 ↗
65. 10.1186/s13045-016-0318-610.1186/s13045-016-0318-6 ↗
66. 10.1158/1535-7163.MCT-13-098210.1158/1535-7163.MCT-13-0982 ↗
67. 10.1073/pnas.220348011910.1073/pnas.2203480119 ↗
68. 10.1016/j.stem.2016.11.00410.1016/j.stem.2016.11.004 ↗
69. 10.1073/pnas.050658010210.1073/pnas.0506580102 ↗
70. 10.1530/ERC-11-032910.1530/ERC-11-0329 ↗